Additives used to reduce perioperative opioid consumption 1: Alpha2-agonists.

Area of Science:

• Anesthesiology
• Pharmacology

Background:

• Routine perioperative opioid use is increasingly questioned due to significant side effects, particularly in obese patients.
• Alpha2-agonists present a viable alternative with considerable analgesic potency.
• These agents act on alpha2-adrenergic receptors in the central nervous system and peripherally.

Purpose of the Study:

• To evaluate the efficacy and safety of alpha2-agonists as alternatives to opioids in perioperative pain management.
• To assess the potential of alpha2-agonists to reduce opioid consumption and associated side effects.

Main Methods:

• Review of existing literature on alpha2-agonists' mechanism of action and clinical applications.
• Analysis of studies comparing alpha2-agonists (e.g., dexmedetomidine) with opioids (e.g., fentanyl) in intraoperative and postoperative settings.

Main Results:

• Alpha2-agonists inhibit central sympathetic outflow, attenuating blood pressure and heart rate.
• They provide postoperative analgesia without respiratory depression and can spare the need for anesthetics and analgesics.
• Intraoperative replacement of fentanyl with dexmedetomidine has been demonstrated.
• Sedation occurs, but recovery times are comparable to opioids.

Conclusions:

• Alpha2-agonists are effective analgesics with a favorable side effect profile compared to opioids, especially regarding respiratory depression.
• Potential cardiovascular side effects like bradycardia and hypotension require monitoring and management.